Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.835 USD | -2.64% | -6.96% | -4.35% |
02:31pm | Shattuck Labs Says FDA Grants Orphan Drug Designation to Leukemia Drug; Shares Rise | MT |
02:20pm | Shattuck Labs Gets FDA's Orphan Drug Status for Leukemia Treatment | DJ |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.54% | 334M | D+ | ||
+51.85% | 57.87B | B- | ||
+41.05% | 40.25B | A | ||
-5.25% | 39.94B | B | ||
-5.16% | 28.54B | C | ||
+12.79% | 26.4B | B- | ||
-20.18% | 19.33B | B | ||
+30.88% | 12.4B | C+ | ||
+0.61% | 12.23B | B+ | ||
+25.06% | 12.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STTK Stock
- Ratings Shattuck Labs, Inc.